Despite the success of immune checkpoint inhibitors in treating solid tumors, inhibition of the PD-1/PD-L1 axis has led to fewer responses in R/R DLBCL (88, 89). This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.